Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</title>
<author><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E." last="Munzone">E. Munzone</name>
<affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>
,<institution>European Institute of Oncology</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A." last="Giobbie-Hurder">A. Giobbie-Hurder</name>
<affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>
,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>
,<addr-line>Boston</addr-line>
,<country>USA</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B. A." last="Gusterson">B. A. Gusterson</name>
<affiliation><nlm:aff id="mdv391_af3"><institution>Institute of Cancer Sciences, Glasgow University</institution>
,<addr-line>Glasgow</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E." last="Mallon">E. Mallon</name>
<affiliation><nlm:aff id="mdv391_af4"><institution>Southern General Hospital</institution>
,<addr-line>Glasgow</addr-line>
,<country>UK</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G." last="Viale">G. Viale</name>
<affiliation><nlm:aff id="mdv391_af5"><addr-line>Department of Pathology and Laboratory Medicine</addr-line>
,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B." last="Thürlimann">B. Thürlimann</name>
<affiliation><nlm:aff id="mdv391_af6"><institution>Breast Center, Kantonsspital</institution>
,<addr-line>St Gallen</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="mdv391_af7"><institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>
,<addr-line>Bern</addr-line>
,<country>Switzerland</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B." last="Ejlertsen">B. Ejlertsen</name>
<affiliation><nlm:aff id="mdv391_af8"><institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>
,<addr-line>Copenhagen</addr-line>
,<country>Denmark</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G." last="Macgrogan">G. Macgrogan</name>
<affiliation><nlm:aff id="mdv391_af9"><addr-line>Department of Pathology</addr-line>
,<institution>Institut Bergonié</institution>
,<addr-line>Bordeaux</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F." last="Bibeau">F. Bibeau</name>
<affiliation><nlm:aff id="mdv391_af10"><addr-line>Department of Pathology</addr-line>
,<institution>Val d'Aurelle Cancer Institute</institution>
,<addr-line>Montpellier</addr-line>
,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G." last="Lelkaitis">G. Lelkaitis</name>
<affiliation><nlm:aff id="mdv391_af11"><addr-line>Department of Pathology</addr-line>
,<institution>Rigshospitalet</institution>
,<addr-line>Copenhagen</addr-line>
,<country>Denmark</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K. N." last="Price">K. N. Price</name>
<affiliation><nlm:aff id="mdv391_af12"><institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R. D." last="Gelber">R. D. Gelber</name>
<affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>
,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>
,<addr-line>Boston</addr-line>
,<country>USA</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="mdv391_af13"><addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>
,<institution>Frontier Science and Technology Research Foundation</institution>
,<addr-line>Boston</addr-line>
,<country>USA</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A. S." last="Coates">A. S. Coates</name>
<affiliation><nlm:aff id="mdv391_af14"><addr-line>International Breast Cancer Study Group, Bern</addr-line>
,<institution>Switzerland</institution>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="mdv391_af15"><institution>University of Sydney</institution>
,<addr-line>Sydney</addr-line>
,<country>Australia</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A." last="Goldhirsch">A. Goldhirsch</name>
<affiliation><nlm:aff id="mdv391_af16"><addr-line>Program of Breast Health</addr-line>
,<institution>European Institute of Oncology</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M." last="Colleoni">M. Colleoni</name>
<affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>
,<institution>European Institute of Oncology</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">26387144</idno>
<idno type="pmc">4658543</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658543</idno>
<idno type="RBID">PMC:4658543</idno>
<idno type="doi">10.1093/annonc/mdv391</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">000169</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000169</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</title>
<author><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E." last="Munzone">E. Munzone</name>
<affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>
,<institution>European Institute of Oncology</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A." last="Giobbie-Hurder">A. Giobbie-Hurder</name>
<affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>
,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>
,<addr-line>Boston</addr-line>
,<country>USA</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B. A." last="Gusterson">B. A. Gusterson</name>
<affiliation><nlm:aff id="mdv391_af3"><institution>Institute of Cancer Sciences, Glasgow University</institution>
,<addr-line>Glasgow</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E." last="Mallon">E. Mallon</name>
<affiliation><nlm:aff id="mdv391_af4"><institution>Southern General Hospital</institution>
,<addr-line>Glasgow</addr-line>
,<country>UK</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G." last="Viale">G. Viale</name>
<affiliation><nlm:aff id="mdv391_af5"><addr-line>Department of Pathology and Laboratory Medicine</addr-line>
,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B." last="Thürlimann">B. Thürlimann</name>
<affiliation><nlm:aff id="mdv391_af6"><institution>Breast Center, Kantonsspital</institution>
,<addr-line>St Gallen</addr-line>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="mdv391_af7"><institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>
,<addr-line>Bern</addr-line>
,<country>Switzerland</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B." last="Ejlertsen">B. Ejlertsen</name>
<affiliation><nlm:aff id="mdv391_af8"><institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>
,<addr-line>Copenhagen</addr-line>
,<country>Denmark</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G." last="Macgrogan">G. Macgrogan</name>
<affiliation><nlm:aff id="mdv391_af9"><addr-line>Department of Pathology</addr-line>
,<institution>Institut Bergonié</institution>
,<addr-line>Bordeaux</addr-line>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F." last="Bibeau">F. Bibeau</name>
<affiliation><nlm:aff id="mdv391_af10"><addr-line>Department of Pathology</addr-line>
,<institution>Val d'Aurelle Cancer Institute</institution>
,<addr-line>Montpellier</addr-line>
,<country>France</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G." last="Lelkaitis">G. Lelkaitis</name>
<affiliation><nlm:aff id="mdv391_af11"><addr-line>Department of Pathology</addr-line>
,<institution>Rigshospitalet</institution>
,<addr-line>Copenhagen</addr-line>
,<country>Denmark</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K. N." last="Price">K. N. Price</name>
<affiliation><nlm:aff id="mdv391_af12"><institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R. D." last="Gelber">R. D. Gelber</name>
<affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>
,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>
,<addr-line>Boston</addr-line>
,<country>USA</country>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="mdv391_af13"><addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>
,<institution>Frontier Science and Technology Research Foundation</institution>
,<addr-line>Boston</addr-line>
,<country>USA</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A. S." last="Coates">A. S. Coates</name>
<affiliation><nlm:aff id="mdv391_af14"><addr-line>International Breast Cancer Study Group, Bern</addr-line>
,<institution>Switzerland</institution>
</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="mdv391_af15"><institution>University of Sydney</institution>
,<addr-line>Sydney</addr-line>
,<country>Australia</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A." last="Goldhirsch">A. Goldhirsch</name>
<affiliation><nlm:aff id="mdv391_af16"><addr-line>Program of Breast Health</addr-line>
,<institution>European Institute of Oncology</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M." last="Colleoni">M. Colleoni</name>
<affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>
,<institution>European Institute of Oncology</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of Oncology</title>
<idno type="ISSN">0923-7534</idno>
<idno type="eISSN">1569-8041</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>In the BIG 1-98 clinical trial of 4922 postmenopausal women treated with 5 years of letrozole or tamoxifen for endocrine-responsive breast cancer, 183 had the rare histotypes mucinous or tubular/cribriform. These women had better outcomes than those with other histotypes. The magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with these rare histotypes.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann. Oncol</journal-id>
<journal-id journal-id-type="publisher-id">annonc</journal-id>
<journal-id journal-id-type="hwp">annonc</journal-id>
<journal-title-group><journal-title>Annals of Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0923-7534</issn>
<issn pub-type="epub">1569-8041</issn>
<publisher><publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">26387144</article-id>
<article-id pub-id-type="pmc">4658543</article-id>
<article-id pub-id-type="doi">10.1093/annonc/mdv391</article-id>
<article-id pub-id-type="publisher-id">mdv391</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject>
<subj-group subj-group-type="heading"><subject>Breast Tumors</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group><article-title>Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Munzone</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af1">1</xref>
<xref ref-type="corresp" rid="mdv391_cor1">*</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Giobbie-Hurder</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Gusterson</surname>
<given-names>B. A.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Mallon</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Viale</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Thürlimann</surname>
<given-names>B.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af6">6</xref>
<xref ref-type="aff" rid="mdv391_af7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Ejlertsen</surname>
<given-names>B.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af8">8</xref>
</contrib>
<contrib contrib-type="author"><name><surname>MacGrogan</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af9">9</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Bibeau</surname>
<given-names>F.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af10">10</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lelkaitis</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af11">11</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Price</surname>
<given-names>K. N.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af12">12</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Gelber</surname>
<given-names>R. D.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af2">2</xref>
<xref ref-type="aff" rid="mdv391_af13">13</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Coates</surname>
<given-names>A. S.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af14">14</xref>
<xref ref-type="aff" rid="mdv391_af15">15</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Goldhirsch</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af16">16</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Colleoni</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="mdv391_af1">1</xref>
</contrib>
<on-behalf-of>for the International Breast Cancer Study Group and the BIG 1-98 Collaborative Group</on-behalf-of>
<aff id="mdv391_af1"><label>1</label>
<addr-line>Division of Medical Senology</addr-line>
,<institution>European Institute of Oncology</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</aff>
<aff id="mdv391_af2"><label>2</label>
<addr-line>Department of Biostatistics and Computational Biology</addr-line>
,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>
,<addr-line>Boston</addr-line>
,<country>USA</country>
</aff>
<aff id="mdv391_af3"><label>3</label>
<institution>Institute of Cancer Sciences, Glasgow University</institution>
,<addr-line>Glasgow</addr-line>
</aff>
<aff id="mdv391_af4"><label>4</label>
<institution>Southern General Hospital</institution>
,<addr-line>Glasgow</addr-line>
,<country>UK</country>
</aff>
<aff id="mdv391_af5"><label>5</label>
<addr-line>Department of Pathology and Laboratory Medicine</addr-line>
,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</aff>
<aff id="mdv391_af6"><label>6</label>
<institution>Breast Center, Kantonsspital</institution>
,<addr-line>St Gallen</addr-line>
</aff>
<aff id="mdv391_af7"><label>7</label>
<institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>
,<addr-line>Bern</addr-line>
,<country>Switzerland</country>
</aff>
<aff id="mdv391_af8"><label>8</label>
<institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>
,<addr-line>Copenhagen</addr-line>
,<country>Denmark</country>
</aff>
<aff id="mdv391_af9"><label>9</label>
<addr-line>Department of Pathology</addr-line>
,<institution>Institut Bergonié</institution>
,<addr-line>Bordeaux</addr-line>
</aff>
<aff id="mdv391_af10"><label>10</label>
<addr-line>Department of Pathology</addr-line>
,<institution>Val d'Aurelle Cancer Institute</institution>
,<addr-line>Montpellier</addr-line>
,<country>France</country>
</aff>
<aff id="mdv391_af11"><label>11</label>
<addr-line>Department of Pathology</addr-line>
,<institution>Rigshospitalet</institution>
,<addr-line>Copenhagen</addr-line>
,<country>Denmark</country>
</aff>
<aff id="mdv391_af12"><label>12</label>
<institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution>
</aff>
<aff id="mdv391_af13"><label>13</label>
<addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>
,<institution>Frontier Science and Technology Research Foundation</institution>
,<addr-line>Boston</addr-line>
,<country>USA</country>
</aff>
<aff id="mdv391_af14"><label>14</label>
<addr-line>International Breast Cancer Study Group, Bern</addr-line>
,<institution>Switzerland</institution>
</aff>
<aff id="mdv391_af15"><label>15</label>
<institution>University of Sydney</institution>
,<addr-line>Sydney</addr-line>
,<country>Australia</country>
</aff>
<aff id="mdv391_af16"><label>16</label>
<addr-line>Program of Breast Health</addr-line>
,<institution>European Institute of Oncology</institution>
,<addr-line>Milan</addr-line>
,<country>Italy</country>
</aff>
</contrib-group>
<author-notes><corresp id="mdv391_cor1"><label>*</label>
<italic>Correspondence to:</italic>
Dr Elisabetta Munzone, Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Tel: +39-02-57489502; E-mail: <email>elisabetta.munzone@ieo.it</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub"><day>19</day>
<month>9</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>1</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pmc-comment> PMC Release delay is 12 months and
0 days and was based on the . </pmc-comment>
<volume>26</volume>
<issue>12</issue>
<fpage>2442</fpage>
<lpage>2449</lpage>
<history><date date-type="received"><day>9</day>
<month>4</month>
<year>2015</year>
</date>
<date date-type="rev-recd"><day>3</day>
<month>9</month>
<year>2015</year>
</date>
<date date-type="accepted"><day>14</day>
<month>9</month>
<year>2015</year>
</date>
</history>
<permissions><copyright-statement>© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="mdv391.pdf"></self-uri>
<abstract abstract-type="precis"><p>In the BIG 1-98 clinical trial of 4922 postmenopausal women treated with 5 years of letrozole or tamoxifen for endocrine-responsive breast cancer, 183 had the rare histotypes mucinous or tubular/cribriform. These women had better outcomes than those with other histotypes. The magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with these rare histotypes.</p>
</abstract>
<abstract><sec><title>Background</title>
<p>We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.</p>
</sec>
<sec><title>Patients and methods</title>
<p>The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (<italic>N</italic>
= 100), tubular/cribriform (<italic>N</italic>
= 83), ductal (<italic>N</italic>
= 3257), and other (<italic>N</italic>
= 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.</p>
</sec>
<sec><title>Results</title>
<p>Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94–11.7; <italic>P</italic>
= 0.06].</p>
</sec>
<sec><title>Conclusions</title>
<p>Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.</p>
</sec>
<sec><title>Clinicaltrials.gov</title>
<p>NCT00004205.</p>
</sec>
</abstract>
<kwd-group><kwd>letrozole</kwd>
<kwd>tamoxifen</kwd>
<kwd>mucinous</kwd>
<kwd>tubular</kwd>
<kwd>cribriform</kwd>
<kwd>breast cancer</kwd>
</kwd-group>
<funding-group><award-group id="funding-1"><funding-source>Novartis <named-content content-type="funder-id">http://dx.doi.org/10.13039/100004336</named-content>
</funding-source>
</award-group>
<award-group id="funding-2"><funding-source>IBCSG: Swedish Cancer Society,</funding-source>
</award-group>
<award-group id="funding-3"><funding-source>US National Institute of Health</funding-source>
</award-group>
<award-group id="funding-4"><funding-source>Foundation for Clinical Cancer Research of Eastern Switzerland</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0001699 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0001699 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
This area was generated with Dilib version V0.6.33. |